| scholarly article | Q13442814 |
| P356 | DOI | 10.2337/DIABETES.44.11.1249 |
| P953 | full work available at URL | http://intl-diabetes.diabetesjournals.org/cgi/content/abstract/44/11/1249 |
| P698 | PubMed publication ID | 7589820 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | diabetic diet | Q899519 |
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 1249-1258 | |
| P577 | publication date | 1995-11-01 | |
| P1433 | published in | Diabetes | Q895262 |
| P1476 | title | U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group | |
| P478 | volume | 44 |
| Q37107776 | A 3-year follow-up study of β-cell function in patients with early-onset type 2 diabetes |
| Q34374321 | A Physiologic and Pharmacological Basis for Implementation of Incretin Hormones in the Treatment of Type 2 Diabetes Mellitus |
| Q57796757 | A Type 1 Diabetes Genetic Risk Score Can Identify Patients With GAD65 Autoantibody-Positive Type 2 Diabetes Who Rapidly Progress to Insulin Therapy |
| Q28542553 | A combined analysis of 48 type 2 diabetes genetic risk variants shows no discriminative value to predict time to first prescription of a glucose lowering drug in Danish patients with screen detected type 2 diabetes |
| Q51483637 | A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. |
| Q36019817 | A critical appraisal of the role of insulin analogues in the management of diabetes mellitus |
| Q58713815 | A higher blood glucose level pre-breakfast in comparison to bedtime is a contraindication for intensification of prandial insulin therapy in patients with type 2 diabetes - The impact of a negative BeAM value |
| Q36519198 | A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies |
| Q45113390 | A pentadecapeptide fragment of islet neogenesis-associated protein increases beta-cell mass and reverses diabetes in C57BL/6J mice. |
| Q35828121 | A practical approach for implementation of a basal-prandial insulin therapy regimen in patients with type 2 diabetes |
| Q35126915 | A randomized controlled trial to prevent glycemic relapse in longitudinal diabetes care: study protocol (NCT00362193). |
| Q51371873 | A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naïve ty |
| Q33678321 | A risk-benefit assessment of metformin in type 2 diabetes mellitus |
| Q34479133 | A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus |
| Q37864217 | AMP-activated protein kinase and metabolic control |
| Q24307433 | ANGPTL8/betatrophin does not control pancreatic beta cell expansion |
| Q35825702 | Abdominal adiposity and daily step counts as determinants of glycemic control in a cohort of patients with type 2 diabetes mellitus |
| Q37221760 | Abnormalities in insulin secretion in type 2 diabetes mellitus |
| Q27025870 | Action and therapeutic potential of oxyntomodulin |
| Q47612364 | Adaptation to myocardial stress in disease states: is preconditioning a healthy heart phenomenon? |
| Q33476850 | Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis |
| Q42660180 | Addition of exogenous sodium palmitate increases the IAPP/insulin mRNA ratio via GPR40 in human EndoC-βH1 cells. |
| Q37015105 | Adequate prescribing of medication does not necessarily translate into good control of diabetes mellitus. |
| Q34025740 | Adipsin is an adipokine that improves β cell function in diabetes |
| Q36007875 | Advances in diabetes for the millennium: understanding insulin resistance |
| Q41277375 | Advances in the treatment of diabetes mellitus in the elderly. Development of insulin analogues |
| Q28083933 | Alogliptin benzoate for management of type 2 diabetes |
| Q26749089 | An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass |
| Q33558360 | An islet in distress: β cell failure in type 2 diabetes |
| Q36164723 | An overview of the rationale for pharmacological strategies in type 2 diabetes: from the evidence to new perspectives |
| Q33585549 | Analysis of factors influencing postprandial C-peptide levels in Japanese patients with type 2 diabetes: Comparison with C-peptide levels after glucagon load |
| Q41974447 | Antidiabetic antihyperlipidemic and hepato-protective effect of Gluconorm-5: A polyherbal formulation in steptozotocin induced hyperglycemic rats |
| Q37505552 | Antidiabetic medications and weight gain: implications for the practicing physician |
| Q36255398 | Antihypertensive drugs and incidence of type 2 diabetes: evidence and implications for clinical practice |
| Q92910500 | Applicability of adipose-derived mesenchymal stem cells in treatment of patients with type 2 diabetes |
| Q34660677 | Applications of economic models in healthcare: the introduction of pioglitazone in Sweden |
| Q51553024 | Appropriate timing of glimepiride administration in patients with type 2 diabetes millitus: a study in Mediterranean countries. |
| Q31122704 | Are hypoglycaemia and other adverse effects similar among sulphonylureas? |
| Q36640590 | Are sulfonylureas passé? |
| Q40309507 | Asparagus adscendens (Shweta musali) stimulates insulin secretion, insulin action and inhibits starch digestion |
| Q51568023 | Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. |
| Q26829445 | Assessment of pancreatic β-cell function: review of methods and clinical applications |
| Q91752941 | Association Between Interleukin-10 Gene (-1082g/A) Polymorphism and Type 2 Diabetes, Diabetes-Related Traits, and Microvascular Complications in the Croatian Population |
| Q34718494 | Association between insulin resistance and development of microalbuminuria in type 2 diabetes: a prospective cohort study |
| Q22242096 | Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study |
| Q36608943 | Autonomy of patients with type 2 diabetes with an insulin pump device: is it predictable? |
| Q33902894 | BLX-1002 restores glucose sensitivity and enhances insulin secretion stimulated by GLP-1 and sulfonylurea in type 2 diabetic pancreatic islets |
| Q37141727 | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus |
| Q43232795 | Banting Memorial lecture 2012: reversing the twin cycles of type 2 diabetes |
| Q37419803 | Bariatric Surgery to Correct Morbid Obesity Also Ameliorates Atherosclerosis in Patients with Type 2 Diabetes Mellitus |
| Q35069674 | Bariatric surgery: an IDF statement for obese Type 2 diabetes |
| Q37587466 | Barriers that practitioners face when initiating insulin therapy in general practice settings and how they can be overcome |
| Q34558840 | Barriers to initiating insulin in type 2 diabetes patients: development of a new patient education tool to address myths, misconceptions and clinical realities. |
| Q40391316 | Beta cell dysfunction in patients with acute myocardial infarction but without previously known type 2 diabetes: a report from the GAMI study |
| Q34318757 | Beta cell response to a mixed meal in nigerian patients with type 2 diabetes. |
| Q37105367 | Beta- and alpha-cell dysfunction in subjects developing impaired glucose tolerance: outcome of a 12-year prospective study in postmenopausal Caucasian women |
| Q35767284 | Beta-cell failure in the pathogenesis of type 2 diabetes mellitus |
| Q37215420 | Beta-cell failure in type 2 diabetes mellitus |
| Q92697166 | Beta-cell function in type 2 diabetic patients who failed to maintain good glycemic status with a combination of maximum dosages of metformin and sulfonylurea |
| Q31935212 | Better glycaemic control and risk reduction of diabetic complications in Type 2 diabetes: comparison with the DCCT. |
| Q34620736 | Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes |
| Q47968558 | Biphasic insulin aspart-30 reduces glycemic variability to a greater degree than insulin detemir: A randomized controlled trial of once-daily insulin regimens using continuous glucose monitoring. |
| Q35916079 | C-Peptide Level in Fasting Plasma and Pooled Urine Predicts HbA1c after Hospitalization in Patients with Type 2 Diabetes Mellitus |
| Q47275144 | Calcium-dependent ultrasound stimulation of secretory events from pancreatic beta cells |
| Q64237221 | Calorie restriction for long-term remission of type 2 diabetes |
| Q40674491 | Can diabetes management programs create sustained improvements in disease outcomes? |
| Q37834962 | Can modeling of health outcomes facilitate regulatory decision making? The benefit-risk tradeoff for rosiglitazone in 1999 vs. 2007. |
| Q50066341 | Cardial target-organ damage in diabetes |
| Q44981468 | Cardiovascular effects of rosiglitazone |
| Q82871420 | Case study: lessons learned in the care of a 63-year-old woman with type 2 diabetes |
| Q21144738 | Case-based study: from prediabetes to complications--opportunities for prevention |
| Q84121720 | Challenges and approaches to managing type 2 diabetes mellitus |
| Q35014936 | Challenges of maintaining research protocol fidelity in a clinical care setting: a qualitative study of the experiences and views of patients and staff participating in a randomized controlled trial |
| Q37364885 | Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme-1 (IDPP-1). |
| Q55312695 | Changes of MODY signal pathway genes in the endoplasmic reticulum stress in INS-1-3 cells. |
| Q37193695 | Characteristics associated with maintenance of mean A1C<6.5% in people with dysglycemia in the ORIGIN trial |
| Q41830874 | Characterization of Micro-RNA Changes during the Progression of Type 2 Diabetes in Zucker Diabetic Fatty Rats |
| Q34721973 | Chinese herbal medicine for impaired glucose tolerance: a randomized placebo controlled trial |
| Q37949599 | Choosing a gliptin |
| Q28575171 | Class II phosphoinositide 3-kinase regulates exocytosis of insulin granules in pancreatic beta cells |
| Q57655935 | Classifying diabetes according to the new WHO clinical stages |
| Q37427304 | Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes |
| Q33686766 | Clinical and genetic determinants of progression of type 2 diabetes: a DIRECT study |
| Q36917168 | Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes |
| Q36608929 | Clinical evaluation of a novel on-strip calibration method for blood glucose measurement |
| Q35087354 | Combination oral agent and insulin therapy for type 2 diabetes mellitus |
| Q38270132 | Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations. |
| Q37416127 | Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. |
| Q36541464 | Combining insulins for optimal blood glucose control in type I and 2 diabetes: focus on insulin glulisine |
| Q36511814 | Common crossroads in diabetes management |
| Q35614295 | Common problems in outpatient management of patients with diabetes in the age of insulin analogues |
| Q37659673 | Comparative effectiveness of liraglutide in the treatment of type 2 diabetes |
| Q33585766 | Comparative efficacy and safety of long-acting insulin analogs in patients with type 2 diabetes failing on oral therapy: Systemic review and meta-analyses |
| Q47554566 | Comparison of Insulin Dose Adjustments by Primary Care Physicians and Endocrinologists |
| Q37404448 | Comparison of lancing devices for self-monitoring of blood glucose regarding lancing pain |
| Q51362596 | Comparison of safety and efficacy of insulin glargine and neutral protamine hagedorn insulin in older adults with type 2 diabetes mellitus: results from a pooled analysis. |
| Q36424020 | Comparison of the Effects of Continuous Subcutaneous Insulin Infusion and Add-On Therapy with Sitagliptin in Patients with Newly Diagnosed Type 2 Diabetes Mellitus |
| Q35838690 | Comparison of thrice daily biphasic human insulin (30/70) versus basal detemir & bolus aspart in patients with poorly controlled type 2 diabetes mellitus - a pilot study |
| Q46583597 | Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy: glycaemic control and quality-of-life of insulin-naïve type 2 diabetic patients |
| Q37796152 | Continuous subcutaneous insulin infusion (CSII) using an external insulin pump for the treatment of type 2 diabetes |
| Q42718202 | Correlates of Medication Adherence in the TODAY Cohort of Youth With Type 2 Diabetes |
| Q35734015 | Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective |
| Q37207605 | Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective |
| Q35551069 | Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin |
| Q34726534 | Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in sweden |
| Q34351961 | Counterpoint: Intensive glucose control and mortality in ACCORD--still looking for clues |
| Q34455151 | Cumulative systolic BP and changes in urine albumin-to-creatinine ratios in nondiabetic participants of the multi-ethnic study of atherosclerosis |
| Q35147057 | Current management strategies for coexisting diabetes mellitus and obesity |
| Q33723387 | Current therapeutic options in type 2 diabetes mellitus: a practical approach |
| Q35874941 | DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from type 2 diabetic patients |
| Q38837492 | DPP-4 inhibitor treatment: β-cell response but not HbA1c reduction is dependent on the duration of diabetes |
| Q33785136 | Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial |
| Q34514280 | Dapagliflozin efficacy and safety: a perspective review. |
| Q34153496 | Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial |
| Q34313024 | Dapagliflozin: a review of its use in type 2 diabetes mellitus |
| Q46875772 | Declining ß-cell function is associated with the lack of long-range negative correlation in glucose dynamics and increased glycemic variability: A retrospective analysis in patients with type 2 diabetes |
| Q35651511 | Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications |
| Q33610728 | Defining and characterizing the progression of type 2 diabetes |
| Q33607736 | Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes. |
| Q52726650 | Delay in glucose peak time during the oral glucose tolerance test as an indicator of insulin resistance and insulin secretion in type 2 diabetes patients. |
| Q33517854 | Design and methods for a randomized clinical trial of a diabetes self-management intervention for low-income Latinos: Latinos en Control |
| Q92977257 | Determinants of poor glycemic control among adult patients with type 2 diabetes mellitus in Jimma University Medical Center, Jimma zone, south west Ethiopia: a case control study |
| Q58081753 | Developing a Simple 3-Day Insulin Delivery Device to Meet the Needs of People With Type 2 Diabetes |
| Q46627810 | Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes-related complications |
| Q38109814 | Diabetes and its comorbidities--where East meets West |
| Q33825754 | Diabetes care in general practice: meta-analysis of randomised control trials |
| Q92572465 | Diabetes causes marked inhibition of mitochondrial metabolism in pancreatic β-cells |
| Q36331397 | Diabetes control among Hispanics in the action to control cardiovascular risk in diabetes trial |
| Q36117595 | Diabetes mellitus: new challenges and innovative therapies |
| Q84879817 | Diabetes: Add-on to metformin in T2DM--linagliptin or glimepiride? |
| Q41107201 | Diabetic complications. The importance of glucose control |
| Q34116264 | Diet control to achieve euglycemia induces significant loss of heart and liver weight via increased autophagy compared with ad libitum diet in diabetic rats |
| Q37205376 | Differences in insulin sensitivity and secretory capacity based on OGTT in subjects with impaired glucose regulation. |
| Q36892807 | Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus |
| Q37900690 | Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence |
| Q37735838 | Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus |
| Q53352969 | Distinct effects of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist on islet morphology and function. |
| Q42996831 | Do insulinotropic glucose-lowering drugs do more harm than good? The hypersecretion hypothesis revisited |
| Q34114513 | Does early intensive multifactorial therapy reduce modelled cardiovascular risk in individuals with screen-detected diabetes? Results from the ADDITION-Europe cluster randomized trial |
| Q43180130 | Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide |
| Q35766925 | Does inhibition of β-cell proliferation by free fatty acid in mice explain the progressive failure of insulin secretion in type 2 diabetes? |
| Q37973874 | Does interference with the renin-angiotensin system protect against diabetes? Evidence and mechanisms |
| Q35187795 | Drug therapy of diabetes in the elderly |
| Q34322132 | Drug titration patterns and HbA 1c levels in type 2 diabetes |
| Q40883325 | Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments |
| Q37799813 | Drug-induced hypoglycaemia: an update |
| Q39404106 | Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options |
| Q50071123 | Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration. |
| Q36424107 | Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial |
| Q38762377 | Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes. |
| Q26767164 | Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials |
| Q36580997 | Early intervention to achieve optimal outcomes in type 2 diabetes: a case presentation |
| Q44511825 | Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus. |
| Q42764571 | Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes |
| Q64282671 | Effect of Remote Glucose Monitoring Utilizing Computerized Insulin Dose Adjustment Algorithms: A Pilot Project |
| Q33683750 | Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial |
| Q64901738 | Effect of antihyperglycemic drug monotherapy to prevent the progression of mild hyperglycemia in early type 2 diabetic patients: the Japan Early Diabetes Intervention Study (JEDIS). |
| Q35106580 | Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial |
| Q34073469 | Effect of exenatide, sitagliptin, or glimepiride on β-cell secretory capacity in early type 2 diabetes |
| Q42496887 | Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes |
| Q37236069 | Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents. |
| Q33558365 | Effect of the combination of mitiglinide and metformin on glycemic control in patients with type 2 diabetes mellitus |
| Q88538234 | Effect of the sodium-glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages |
| Q57093273 | Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study |
| Q61812816 | Effects of Coffee and Tea Consumption on Glucose Metabolism: A Systematic Review and Network Meta-Analysis |
| Q64269628 | Effects of Periodic Intensive Insulin Therapy: An Updated Review |
| Q37445774 | Effects of Roux-en-Y gastric bypass or diabetes support and education on insulin sensitivity and insulin secretion in morbidly obese patients with type 2 diabetes |
| Q42101166 | Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes |
| Q35179964 | Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes |
| Q51474263 | Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up. |
| Q35857481 | Effects of laparoscopic gastric plication (LGP) in patients with type 2 diabetes, one year follow-up |
| Q35797022 | Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT. |
| Q34273302 | Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes |
| Q40998901 | Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial |
| Q92493277 | Effects of the fenugreek extracts on high-fat diet-fed and streptozotocin-induced type 2 diabetic mice |
| Q51206578 | Effects of vildagliptin/metformin therapy on patient-reported outcomes: work productivity, patient satisfaction, and resource utilization. |
| Q90703785 | Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1 |
| Q39489588 | Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study |
| Q34598940 | Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study |
| Q51554500 | Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. |
| Q26749095 | Efficacy and safety of biphasic insulin aspart and biphasic insulin lispro mix in patients with type 2 diabetes: A review of the literature |
| Q33558408 | Efficacy and safety of patient-directed titration of once-daily pre-dinner premixed biphasic insulin aspart 70/30 injection in Japanese type 2 diabetic patients with oral antidiabetic drug failure: STEP-AKITA study |
| Q37095123 | Efficacy and safety of pioglitazone in type 2 diabetes in the Indian patients: Results of an observational study |
| Q35087917 | Efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes |
| Q51478110 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. |
| Q38285665 | Efficacy and tolerability of GLP-1 agonists in patients with type 2 diabetes mellitus: an Indian perspective |
| Q94430488 | Efficacy of oral versus insulin therapy for newly diagnosed diabetes in low-income settings |
| Q38462847 | Elevated A1C is associated with impaired early-phase insulin secretion rather than insulin resistance in Koreans at high risk for developing diabetes |
| Q28762629 | Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes |
| Q33622195 | Equivalent weight loss with marked metabolic benefit observed in a matched cohort with and without type 2 diabetes 12 months following gastric bypass surgery |
| Q51736812 | Errors of insulin therapy: Real-life experiences from developing world. |
| Q46142568 | Establishing an evidence base for frequency of monitoring glycated haemoglobin levels in patients with Type 2 diabetes: projections of effectiveness from a regression model |
| Q33774989 | Estimation of insulin secretion, glucose uptake by tissues, and liver handling of glucose using a mathematical model of glucose-insulin homeostasis in lean and obese mice |
| Q34299641 | Evaluation of insulin regimens as an effective option for glycemic control in patients with type 2 diabetes: A propensity score-matched cohort study across Japan (JDDM31) |
| Q36877205 | Evolution of exenatide as a diabetes therapeutic |
| Q80974729 | Exenatide |
| Q36656331 | Exenatide Treatment Causes Suppression of Serum Ghrelin Levels following Mixed Meal Test in Obese Diabetic Women. |
| Q47567913 | Exenatide treatment causes suppression of serum fasting ghrelin levels in patients with type 2 diabetes mellitus |
| Q34618193 | Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). |
| Q36235047 | Factors associated with no apparent coronary artery disease in patients with type 2 diabetes mellitus for more than 10 years of duration: a case control study. |
| Q34015994 | Factors associated with psychological insulin resistance in individuals with type 2 diabetes |
| Q50067146 | Failure of monotherapy in clinical practice in patients with type 2 diabetes: The Korean National Diabetes Program |
| Q37189508 | Failure to initiate early insulin therapy - A risk factor for diabetic retinopathy in insulin users with Type 2 diabetes mellitus: Sankara Nethralaya-Diabetic Retinopathy Epidemiology and Molecular Genetics Study (SN-DREAMS, Report number 35). |
| Q36669613 | Fallacies of last observation carried forward analyses |
| Q57492963 | Five-Year Predictors of Insulin Initiation in People with Type 2 Diabetes under Real-Life Conditions |
| Q34366918 | Gastrointestinal metabolic surgery for the treatment of type 2 diabetes mellitus |
| Q64059617 | Genetic obesity increases pancreatic expression of mitochondrial proteins which regulate cholesterol efflux in BRIN-BD11 insulinoma cells |
| Q37239219 | Gingival crevicular blood: As a non-invasive screening tool for diabetes mellitus in dental clinics |
| Q42009138 | Glibenclamide or metformin combined with honey improves glycemic control in streptozotocin-induced diabetic rats |
| Q24235918 | Glucagon-like peptide analogues for type 2 diabetes mellitus |
| Q33767049 | Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis |
| Q35136457 | Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials |
| Q33665283 | Glucolipotoxicity of the pancreatic beta cell. |
| Q36861036 | Glucolipotoxicity: fuel excess and beta-cell dysfunction. |
| Q35244027 | Glucometric assessment of gingival crevicular blood in diabetic and non-diabetic patients: A randomized clinical trial |
| Q33828255 | Glucose supply and insulin demand dynamics of antidiabetic agents |
| Q33638094 | Glucose-lowering therapies, adequacy of metabolic control, and their relationship with comorbid depression in outpatients with type 2 diabetes in a tertiary hospital in Kenya |
| Q36429827 | Glucose-responsive artificial promoter-mediated insulin gene transfer improves glucose control in diabetic mice. |
| Q51309415 | Glycaemic control in patients with type 2 diabetes switching from premixed insulin to long-acting basal insulin analogue plus oral antidiabetic drugs: an observational study. |
| Q51244385 | Glycaemic control in type 2 diabetes patients and its predictors: a retrospective database study at a tertiary care diabetes centre in Ningbo, China. |
| Q46919852 | Glycaemic responsiveness to long-term insulin plus sulphonylurea therapy as assessed by sulphonylurea withdrawal |
| Q92152481 | Glycaemic, blood pressure and low-density lipoprotein-cholesterol control among patients with diabetes mellitus in a specialised clinic in Botswana: a cross-sectional study |
| Q35898200 | Glycemic control over 5 years in 4,900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort. |
| Q34486820 | Glycemic variability and oxidative stress: a link between diabetes and cardiovascular disease? |
| Q33610661 | Goals of treatment for type 2 diabetes: beta-cell preservation for glycemic control |
| Q33814212 | High density lipoproteins and type 2 diabetes: Emerging concepts in their relationship. |
| Q45288341 | High glucose and hydrogen peroxide increase c-Myc and haeme-oxygenase 1 mRNA levels in rat pancreatic islets without activating NFkappaB. |
| Q36640585 | How do different GLP-1 mimetics differ in their actions? |
| Q37577129 | How do we continue treatment in patients with type 2 diabetes when therapeutic goals are not reached with oral antidiabetes agents and lifestyle? Incretin versus insulin treatment |
| Q42590748 | Hypoglycaemic and coronary risk index lowering effects of Bauhinia thoningii in alloxan induced diabetic rats |
| Q45279074 | Hypoglycemia despite hyperglycemia. Is a cerebral glucose deficiency possible even with raised blood sugar levels? |
| Q90152701 | Hypoglycemia during Short-Term Intensive Insulin Therapy and Its Association with Long-Term Glycemic Remission in Patients with Newly Diagnosed Type 2 Diabetes |
| Q39773268 | Hypoglycemia education needs |
| Q84817639 | Hypoglycemia unawareness |
| Q38738725 | IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting |
| Q37115715 | Identification and treatment of prediabetes to prevent progression to type 2 diabetes |
| Q46028078 | Identification and treatment of prediabetes to prevent progression to type 2 diabetes. |
| Q93185320 | Impact of Ginkgo biloba extract and magnetized water on the survival rate and functional capabilities of pancreatic β-cells in type 2 diabetic rat model |
| Q90684014 | Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the SUSTAIN 1-5 trials |
| Q28587870 | Impaired insulin secretion and glucose tolerance in beta cell-selective Ca(v)1.2 Ca2+ channel null mice |
| Q33563331 | Impaired β cell function in Chinese newly diagnosed type 2 diabetes mellitus with hyperlipidemia. |
| Q35667116 | Importance of Beta Cell Function for the Treatment of Type 2 Diabetes |
| Q33423012 | Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics |
| Q60912730 | In vivo monitoring of intracellular Ca dynamics in the pancreatic β-cells of zebrafish embryos |
| Q33775600 | Inadequate Triglyceride Management Worsens the Durability of Dipeptidyl Peptidase-4 Inhibitor in Subjects with Type 2 Diabetes Mellitus |
| Q35043324 | Incidence of diabetes following ramipril or rosiglitazone withdrawal |
| Q34374336 | Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors |
| Q39988564 | Incretin effects on β-cell function, replication, and mass: the human perspective |
| Q36407215 | Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus |
| Q38069507 | Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction |
| Q37760515 | Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects |
| Q92913008 | Individualised targets for insulin initiation in type 2 diabetes mellitus-the influence of physician and practice: a cross-sectional study in eight European countries |
| Q58800465 | Individualized Meal Replacement Therapy Improves Clinically Relevant Long-Term Glycemic Control in Poorly Controlled Type 2 Diabetes Patients |
| Q42642141 | Influence of BMI, Age and duration of diabetes mellitus on glycaemic control with twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart (JDDM 18): retrospective reanalysis of a 6-month, randomized, o |
| Q44740682 | Influence of hemodialysis on incretin hormones and insulin secretion in diabetic and non-diabetic patients |
| Q41280633 | Inhibition of beta-cell sodium-calcium exchange enhances glucose-dependent elevations in cytoplasmic calcium and insulin secretion. |
| Q51378688 | Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. |
| Q42359993 | Initial sulfonylurea use and subsequent insulin therapy in older subjects with type 2 diabetes mellitus |
| Q33610830 | Initiating insulin therapy in type 2 diabetic patients failing on oral hypoglycemic agents: basal or prandial insulin? The APOLLO trial and beyond |
| Q26750895 | Insulin delivery methods: Past, present and future |
| Q36012923 | Insulin glargine in the treatment of type 1 and type 2 diabetes |
| Q38008005 | Insulin initiation in type 2 diabetes: what are the treatment regimen options and how can we best help patients feel empowered? |
| Q37577120 | Insulin pump for type 2 diabetes: use and misuse of continuous subcutaneous insulin infusion in type 2 diabetes |
| Q54105933 | Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities. |
| Q74556183 | Insulin resistance: current concepts |
| Q35219417 | Insulin therapy for type 2 diabetes |
| Q36920613 | Insulin therapy in diabetes mellitus: how can the currently available injectable insulins be most prudently and efficaciously utilised? |
| Q37461707 | Insulin therapy in people with type 2 diabetes: opportunities and challenges? |
| Q34524568 | Insulin therapy: optimizing control in type 1 and type 2 diabetes |
| Q41855774 | Insulin versus an oral antidiabetic agent as add-on therapy in type 2 diabetes after failure of an oral antidiabetic regimen: a meta-analysis |
| Q37364945 | Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better? |
| Q41844759 | Is beta-cell failure in type 2 diabetes mellitus reversible? |
| Q80166381 | Is initial combination therapy effective in the treatment of type 2 diabetes? |
| Q41906566 | Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Some case reports from India |
| Q36786991 | Islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes |
| Q38138370 | K(ATP) channels and islet hormone secretion: new insights and controversies |
| Q33712562 | Lack of preservation of insulin gene expression by a glucagon-like peptide 1 agonist or a dipeptidyl peptidase 4 inhibitor in an in vivo model of glucolipotoxicity |
| Q36139090 | Liraglutide in adults with type 2 diabetes: global perspective on safety, efficacy and patient preference |
| Q38901991 | Lixisenatide as add-on treatment among patients with different β-cell function levels as assessed by HOMA-β index |
| Q37268207 | Long-term activation of PKA in β-cells provides sustained improvement to glucose control, insulin sensitivity and body weight |
| Q34347844 | Long-term effect of metformin on blood glucose control in non-obese patients with type 2 diabetes mellitus |
| Q46486537 | Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes |
| Q37215500 | Longitudinal decline of β-cell function: comparison of a direct method vs a fasting surrogate measure: the Insulin Resistance Atherosclerosis Study |
| Q34656261 | Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy |
| Q46467777 | Low glycaemic index diet and disposition index in type 2 diabetes (the Canadian trial of carbohydrates in diabetes): a randomised controlled trial |
| Q48199510 | Lower mean blood glucose during short-term intensive insulin therapy is associated with long-term glycemic remission in patients with newly diagnosed type 2 diabetes: Evidence-based recommendations for standardization. |
| Q37102861 | Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes |
| Q35032717 | Mayombian ethnic, vegetables low intake, insulin treatment, diabetic nephropathy and severe diabetic retinopathy are determinants of blindness in diabetic Africans |
| Q30241947 | Mechanisms of diabetes mellitus-induced bone fragility |
| Q33869737 | Mechanisms of insulin resistance after insulin-induced hypoglycemia in humans: the role of lipolysis |
| Q34862358 | Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes |
| Q24642503 | Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes |
| Q35614319 | Medical myths involving diabetes |
| Q24245352 | Meglitinide analogues for type 2 diabetes mellitus |
| Q37022586 | Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment |
| Q34128192 | Metabolic syndrome, dyslipidemia, hypertension and type 2 diabetes in youth: from diagnosis to treatment |
| Q41603308 | Metformin |
| Q33959731 | Metformin pharmacogenomics: current status and future directions |
| Q33421729 | Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus |
| Q74480450 | Morbidity in 565 type 2 diabetic patients according to stage of nephropathy |
| Q37828337 | Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies |
| Q37105194 | Natural history of insulin sensitivity and insulin secretion in the progression from normal glucose tolerance to impaired fasting glycemia and impaired glucose tolerance: the Inter99 study |
| Q37727562 | Natural products for type II diabetes treatment |
| Q57069272 | Neuroprotective Effects of Amylin Analogues on Alzheimer's Disease Pathogenesis and Cognition |
| Q36008854 | New approach to beta cell function screening by nitric oxide assessment of obese individuals at the population level |
| Q39626084 | New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser |
| Q37004040 | New combination treatments in the management of diabetes: focus on sitagliptin-metformin |
| Q81066818 | New concepts for treatment of non-insulin-dependent diabetes mellitus |
| Q51559528 | New diabetes screening criteria for midlife women evaluated for coronary heart disease risk. |
| Q38555254 | New insights into the architecture of the islet of Langerhans: a focused cross-species assessment. |
| Q36978852 | Nocturnal hypoglycemia: answering the challenge with long-acting insulin analogs. |
| Q37992259 | Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide |
| Q33610864 | Nonpharmacologic therapy and exercise in the prevention of type 2 diabetes |
| Q48156952 | Normal meal tolerance test is preferable to the glucagon stimulation test in patients with type 2 diabetes that are not in a hyperglycemic state: Comparison with the change of C-peptide immunoreactivity. |
| Q35221336 | Novel views on new-onset diabetes after transplantation: development, prevention and treatment. |
| Q83782939 | Obesity and diabetes: the impact of bariatric surgery on type-2 diabetes |
| Q53863099 | Obesity and fat quantification in lean tissues using three-point Dixon MR imaging. |
| Q36131593 | Opportunities for using lipoprotein subclass profile by nuclear magnetic resonance spectroscopy in assessing insulin resistance and diabetes prediction |
| Q33488897 | Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses |
| Q34113354 | Optimising the medical management of hyperglycaemia in type 2 diabetes in the Middle East: pivotal role of metformin |
| Q37199304 | Optimum management of type 2 diabetes--timely introduction, optimization and intensification of basal insulin |
| Q41722668 | Oral antidiabetic agents. A guide to selection |
| Q41277363 | Oral antidiabetic drug use in the elderly |
| Q34592210 | Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes |
| Q34451776 | Oral therapies for diabetic hyperglycemia |
| Q36812759 | Orlistat in the prevention of diabetes in the obese patient |
| Q37115724 | Overcoming patient barriers to initiating insulin therapy in type 2 diabetes mellitus |
| Q46028075 | Overcoming patient barriers to initiating insulin therapy in type 2 diabetes mellitus. |
| Q36580989 | Overcoming psychological barriers to insulin use in type 2 diabetes |
| Q91790934 | Oxidative Stress and Microvascular Alterations in Diabetic Retinopathy: Future Therapies |
| Q38784851 | Pair Feeding, but Not Insulin, Phloridzin, or Rosiglitazone Treatment, Curtails Markers of β-Cell Dedifferentiation in db/db Mice |
| Q92228016 | Pancreatic stellate cells in the islets as a novel target to preserve the pancreatic β-cell mass and function |
| Q36942158 | Pancreatic β-cell dysfunction and risk of new-onset diabetes after kidney transplantation |
| Q89749129 | Paracrine signaling in islet function and survival |
| Q35561878 | Parameters measuring beta-cell function are only valuable in diabetic subjects with low body mass index, high blood glucose level, or long-standing diabetes |
| Q44136348 | Pathogenesis of type 2 diabetes mellitus |
| Q34008292 | Pathologic changes and glucose homeostasis according to expression of human islet amyloid polypeptide in type 2 diabetic patients |
| Q37577162 | Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes |
| Q37729725 | Patient considerations in the management of type 2 diabetes - critical appraisal of dapagliflozin |
| Q34169097 | Patients with type 2 diabetes mellitus failing on oral agents and starting once daily insulin regimen; a small randomized study investigating effects of adding vildagliptin |
| Q98178542 | Performance of Point-of-Care Testing Compared with the Standard Laboratory Diagnostic Test in the Measurement of HbA1c in Indonesian Diabetic and Nondiabetic Subjects |
| Q30438373 | Peroxisome proliferator-activated receptor gamma activation restores islet function in diabetic mice through reduction of endoplasmic reticulum stress and maintenance of euchromatin structure |
| Q33805824 | Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach |
| Q34810165 | Personalizing guidelines for diabetes management: twilight or dawn of the expert? |
| Q33566802 | Pharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetes |
| Q44013969 | Pharmacokinetics and pharmacodynamics of extended-release glipizide GITS compared with immediate-release glipizide in patients with type II diabetes mellitus |
| Q37641326 | Pharmacokinetics and pharmacodynamics of liraglutide, a long-acting, potent glucagon-like peptide-1 analog |
| Q46438885 | Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects |
| Q34620493 | Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes. |
| Q46883819 | Pioglitazone: a review of its use in type 2 diabetes mellitus |
| Q39987991 | Pivotal role of timely basal insulin replacement after metformin failure in sustaining long-term blood glucose control at a target in type 2 diabetes. |
| Q42931796 | Plasma C-peptide level is inversely associated with family history of type 2 diabetes in Korean type 2 diabetic patients |
| Q34909331 | Point-of-Care HbA1c Testing with the A1cNow Test Kit in General Practice Dental Clinics: A Pilot Study Involving Its Accuracy and Practical Issues in Its Use. |
| Q35846713 | Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. |
| Q34104455 | Possible role of interleukin-1β in type 2 diabetes onset and implications for anti-inflammatory therapy strategies |
| Q33756059 | Post-meal β-cell function predicts the efficacy of glycemic control in patients with type 2 diabetes inadequately controlled by metformin monotherapy after addition of glibenclamide or acarbose |
| Q26747696 | Postprandial C-Peptide to Glucose Ratio as a Marker of β Cell Function: Implication for the Management of Type 2 Diabetes |
| Q34299622 | Postprandial C-peptide to glucose ratio as a predictor of β-cell function and its usefulness for staged management of type 2 diabetes |
| Q33607770 | Postprandial serum C-peptide value is the optimal index to identify patients with non-obese type 2 diabetes who require multiple daily insulin injection: Analysis of C-peptide values before and after short-term intensive insulin therapy |
| Q37940632 | Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants |
| Q77306744 | Potential of alpha-glucosidase inhibitors in elderly patients with diabetes mellitus and impaired glucose tolerance |
| Q37428579 | Practical guidance on intensification of insulin therapy with BIAsp 30: a consensus statement |
| Q30939844 | Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data |
| Q36012965 | Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes |
| Q36640576 | Pramlintide: A new tool in diabetes management |
| Q35087456 | Prediabetes mellitus and its links to atherosclerosis |
| Q42283864 | Predicted blood glucose from insulin administration based on values from miscoded glucose meters |
| Q30837768 | Predictive Value of Cumulative Blood Pressure for All-Cause Mortality and Cardiovascular Events |
| Q33609805 | Predictor variables and an equation for estimating HbA1c attainable by initiation of basal supported oral therapy. |
| Q33912491 | Predictors for attending annual eye screening for diabetic retinopathy amongst patients with diabetes in an urban community of Beijing |
| Q35662169 | Predictors of poor glycaemic control in older patients with type 2 diabetes mellitus |
| Q33809568 | Prevalence rate of diabetes mellitus and impaired fasting glycemia in Hungary: cross-sectional study on nationally representative sample of people aged 20-69 years. |
| Q57168592 | Prevention and Management of Severe Hypoglycemia and Hypoglycemia Unawareness: Incorporating Sensor Technology |
| Q33980529 | Pro's and con's of the early use of insulin in the management of type 2 diabetes: a clinical evaluation |
| Q33585856 | Progressive deterioration of insulin secretion in Japanese type 2 diabetic patients in comparison with those who carry the S20G mutation of the islet amyloid polypeptide gene: A long-term follow-up study |
| Q92926186 | Proinsulin is sensitive to reflect glucose intolerance |
| Q51316929 | Protective effect of Schisandrae chinensis oil on pancreatic β-cells in diabetic rats. |
| Q35126777 | Provider beliefs about diabetes treatment have little impact on glycemic control of their patients with diabetes |
| Q37336667 | Psychological insulin resistance: patient beliefs and implications for diabetes management |
| Q37952293 | Psychological resistance to insulin therapy in adults with type 2 diabetes: mixed-method systematic review |
| Q33851584 | Randomised controlled trial of patient centred care of diabetes in general practice: impact on current wellbeing and future disease risk. The Diabetes Care From Diagnosis Research Team |
| Q41673841 | Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4. |
| Q35132429 | Rapid deterioration of insulin secretion in obese adolescents preceding the onset of type 2 diabetes. |
| Q47279292 | Rates of glycaemic deterioration in a real-world population with type 2 diabetes. |
| Q26999467 | Recent pharmacological developments on rhodanines and 2,4-thiazolidinediones |
| Q37167551 | Redefining the role of thiazolidinediones in the management of type 2 diabetes |
| Q43071629 | Regulation of pancreatic juxtaductal endocrine cell formation by FoxO1. |
| Q36843917 | Relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetic patients (JDDM38). |
| Q35644054 | Relationship between thioredoxin-interacting protein (TXNIP) and islet β-cell dysfunction in patients with impaired glucose tolerance and hypertriglyceridemia |
| Q36310337 | Relationship of Hemoglobin A1c with β Cell Function and Insulin Resistance in Newly Diagnosed and Drug Naive Type 2 Diabetes Patients |
| Q50182622 | Remission of hyperglycemia after withdrawal of oral antidiabetic drugs in Japanese patients with early stage of type 2 diabetes. |
| Q35751679 | Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus |
| Q34385405 | Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus |
| Q42419452 | Response to Comment on: Harrison et al. β-cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care 2012;35:1406-1412. |
| Q82463588 | Retrospective Analysis and Patient Satisfaction Assessment of Insulin Pump Therapy in Patients with Type 2 Diabetes |
| Q48359540 | Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes patients: The association between remaining β-cell function and the achievement of the glycated hemoglobin target 1 year after initiation. |
| Q33607749 | Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β-cell function. |
| Q34191173 | Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. |
| Q91710305 | Review of Ongoing Activities and Challenges to Improve the Care of Patients With Type 2 Diabetes Across Africa and the Implications for the Future |
| Q64085679 | Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial |
| Q24235718 | Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus |
| Q24240522 | Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus |
| Q94362628 | Role of Self-Efficacy in the Relationship Between Patient-Provider Relationships and Psychological Insulin Resistance Among Patients with Type 2 Diabetes |
| Q38592508 | Role of insulin in the regulation of human skeletal muscle protein synthesis and breakdown: a systematic review and meta-analysis |
| Q35987411 | Rosiglitazone RECORD study: glucose control outcomes at 18 months |
| Q46598346 | Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients |
| Q24243875 | Rosiglitazone for type 2 diabetes mellitus |
| Q48122512 | Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: A randomized controlled trial. |
| Q47096334 | Saxagliptin Induces β-Cell Proliferation through Increasing Stromal Cell-Derived Factor-1α In Vivo and In Vitro |
| Q87262274 | Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy |
| Q36139126 | Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus |
| Q34753635 | Screening, prevention, counseling, and treatment for the complications of type II diabetes mellitus. Putting evidence into practice |
| Q35496591 | Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis |
| Q46520634 | Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus |
| Q34299664 | Secretory units of islets in transplantation index is a useful predictor of insulin requirement in Japanese type 2 diabetic patients |
| Q36807640 | Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice |
| Q37736448 | Self-Monitoring of Blood Glucose to Assess Dawn Phenomenon in Chinese People with Type 2 Diabetes Mellitus. |
| Q37405143 | Self-monitoring of blood glucose in diabetes mellitus: arguments for an individualized approach |
| Q38068629 | Self-titration of insulin in the management of people with type 2 diabetes: a practical solution to improve management in primary care |
| Q35549916 | Serum C-peptide assay of patients with hyperglycemic emergencies at the Lagos State University Teaching Hospital (LASUTH), Ikeja |
| Q35135880 | Severe hypoglycemia in adults |
| Q51682171 | Should the algorithm for the treatment of type 2 diabetes be evidence-based? |
| Q51346088 | Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities--the BEGAMI study. |
| Q36625527 | Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial |
| Q35010284 | Six-year follow-up of pancreatic beta cell function in adults with latent autoimmune diabetes |
| Q35612392 | Small-molecule agonists for the glucagon-like peptide 1 receptor |
| Q37703184 | Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus |
| Q55345306 | Solute Carrier Family 30 Member 8 Gene 807C/T Polymorphism and Type 2 Diabetes Mellitus in the Chinese Population: A Meta-Analysis Including 6,942 Subjects. |
| Q37039638 | Spatio-temporal analysis of type 2 diabetes mellitus based on differential expression networks. |
| Q37412792 | Standards of care for type 2 diabetes in China. |
| Q42024048 | Starting insulin in type 2 diabetes: Overcoming barriers to insulin therapy |
| Q41603300 | Sulfonylureas |
| Q41063243 | Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? |
| Q92334143 | Supporting people with type 2 diabetes in effective use of their medicine through mobile health technology integrated with clinical care (SuMMiT-D Feasibility): a randomised feasibility trial protocol |
| Q37319117 | Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. |
| Q27301723 | Systematic development of a theory-informed multifaceted behavioural intervention to increase physical activity of adults with type 2 diabetes in routine primary care: Movement as Medicine for Type 2 Diabetes |
| Q38317168 | Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus |
| Q42954535 | TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats |
| Q41603358 | Tactics for type II diabetes |
| Q36973806 | Tagatose, a new antidiabetic and obesity control drug |
| Q33610724 | Target for glycemic control: concentrating on glucose |
| Q37270524 | Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors |
| Q37091579 | Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins |
| Q46381353 | Targeting prandial hyperglycemia: how important is it and how best to do this? |
| Q37180980 | Targeting the AMPK pathway for the treatment of Type 2 diabetes |
| Q33444254 | The ADDITION-Cambridge trial protocol: a cluster -- randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients |
| Q37253186 | The Efficacy and Safety of Chinese Herbal Decoction in Type 2 Diabetes: A 5-Year Retrospective Study. |
| Q51572062 | The Fasting Hyperglycaemia Study: I. Subject identification and recruitment for a non-insulin-dependent diabetes prevention trial. |
| Q51572059 | The Fasting Hyperglycaemia Study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose. |
| Q37763540 | The Incretins and Pancreatic beta-Cells: Use of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide to Cure Type 2 Diabetes Mellitus |
| Q73923003 | The JEVIN trial: a population-based survey on the quality of diabetes care in Germany: 1994/1995 compared to 1989/1990 |
| Q47755685 | The advanced-DiaRem score improves prediction of diabetes remission 1 year post-Roux-en-Y gastric bypass |
| Q33781660 | The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms |
| Q33757756 | The association between serum uric acid and residual β -cell function in type 2 diabetes |
| Q35067239 | The association of unintentional changes in weight, body composition, and homeostasis model assessment index with glycemic progression in non-diabetic healthy subjects |
| Q34399616 | The case against aggressive treatment of type 2 diabetes: critique of the UK prospective diabetes study |
| Q33969575 | The changes in early phase insulin secretion in newly diagnosed, drug naive korean prediabetes subjects |
| Q33577817 | The characteristics of newly diagnosed adult early-onset diabetes: a population-based cross-sectional study |
| Q49928678 | The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analy |
| Q73534396 | The compliance of hypocaloric diet in type 2 diabetic obese patients: a brief-term study |
| Q37992253 | The design of the liraglutide clinical trial programme |
| Q37336865 | The effects of linagliptin on endothelial function and global arginine bioavailability ratio in coronary artery disease patients with early diabetes: study protocol for a randomized controlled trial. |
| Q36521262 | The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial |
| Q30365939 | The entero-insular axis: implications for human metabolism. |
| Q35688754 | The fate of Beta-cells in type 2 diabetes and the possible role of pharmacological interventions |
| Q35181801 | The glucagon-like peptides: a double-edged therapeutic sword? |
| Q33826388 | The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes |
| Q35049130 | The hypoglycaemic activity of fenugreek seed extract is mediated through the stimulation of an insulin signalling pathway |
| Q35612777 | The impact of the angiotensin-converting enzyme insertion/deletion polymorphism on severe hypoglycemia in Type 2 diabetes |
| Q34095570 | The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth |
| Q33776092 | The incretin system and cardiometabolic disease |
| Q28534790 | The longitudinal association between depressive symptoms and initiation of insulin therapy in people with type 2 diabetes in primary care |
| Q36063768 | The management of type 2 diabetes mellitus in children and adolescents |
| Q35909101 | The management of type 2 diabetic patients with hypoglycemic agents |
| Q37940036 | The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. |
| Q33752794 | The use of insulin alone and in combination with oral agents in type 2 diabetes |
| Q51351946 | Therapeutic efficacy of melatonin in reducing retinal damage in an experimental model of early type 2 diabetes in rats. |
| Q45169500 | Therapeutic management of orally treated type 2 diabetic patients, by French general practitioners in 2010: the DIAttitude Study |
| Q39684381 | Time perspective and weight management behaviors in newly diagnosed Type 2 diabetes: a mediational analysis |
| Q33629776 | Time-cumulated blood pressure exposure and incident impairment of glucose tolerance and diabetes mellitus |
| Q42390253 | Timely insulin use: Need for social marketing |
| Q33699538 | Trajectories in glycemic control over time are associated with cognitive performance in elderly subjects with type 2 diabetes |
| Q51158595 | Transaminase levels in the upper normal range are associated with oral hypoglycemic drug therapy failure in patients with type 2 diabetes. |
| Q47307022 | Translating aetiological insight into sustainable management of type 2 diabetes. |
| Q42656728 | Treating psychological insulin resistance in type 2 diabetes |
| Q39243208 | Treatment of type 2 diabetes in youth: An argument for randomized controlled studies. |
| Q30384663 | Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes: A Post Hoc Analysis of the BARI 2D. |
| Q46610477 | Twenty-four hour insulin secretion and beta cell NEFA oxidation in type 2 diabetic, morbidly obese patients before and after bariatric surgery. |
| Q90019779 | Type 2 diabetes - unmet need, unresolved pathogenesis, mTORC1-centric paradigm |
| Q34023548 | Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? |
| Q34225769 | Type 2 diabetes mellitus and CA 19-9 levels |
| Q37705332 | Type 2 diabetes mellitus is associated with increased risk of pancreatic cancer: A veteran administration registry study |
| Q37837496 | Type 2 diabetes mellitus--current therapies and the emergence of surgical options |
| Q84724987 | Type 2 diabetes: remission in just a week |
| Q27001704 | Unraveling oxyntomodulin, GLP1's enigmatic brother |
| Q37217511 | Update on insulin therapy for type 2 diabetes |
| Q58448043 | Upregulation of alpha cell glucagon-like peptide 1 (GLP-1) in Psammomys obesus—an adaptive response to hyperglycaemia? |
| Q33585873 | Utility of indices using C-peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patients with type 2 diabetes |
| Q37313418 | Vildagliptin: a review of its use in the management of type 2 diabetes mellitus. |
| Q47294991 | Weight gain in type 2 diabetes mellitus |
| Q36735575 | When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study |
| Q38721614 | Which Patients Will Benefit from a Switch in Therapy from Premixed Insulin to Insulin Glargine plus Oral Antidiabetic Drugs? Further Analysis of the Lantus Registry Study. |
| Q75198629 | [Hypoglycemia, classification, therapy and preventable errors] |
| Q49955808 | β-Cell Function Over Time in Adolescents With New Type 2 Diabetes and Obese Adolescents Without Diabetes |
| Q27692665 | β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes |
Search more.